Cargando…

Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up

Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carnicer-Cáceres, Clara, Arranz-Amo, Jose Antonio, Cea-Arestin, Cristina, Camprodon-Gomez, Maria, Moreno-Martinez, David, Lucas-Del-Pozo, Sara, Moltó-Abad, Marc, Tigri-Santiña, Ariadna, Agraz-Pamplona, Irene, Rodriguez-Palomares, Jose F, Hernández-Vara, Jorge, Armengol-Bellapart, Mar, del-Toro-Riera, Mireia, Pintos-Morell, Guillem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068937/ https://www.ncbi.nlm.nih.gov/pubmed/33924567 http://dx.doi.org/10.3390/jcm10081664

Ejemplares similares

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Spanish Fabry and Gaucher disease patients show striking differences in Beliefs about Medicines (BMQ) and Brief Illness Perception (BIPQ) questionnaires
por: González-Lamuño, Domingo, et al.
Publicado: (2022)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
por: Ramaswami, Uma, et al.
Publicado: (2012)

Paediatric Fabry disease: prognostic significance of ocular changes for disease severity
por: Kalkum, Gisela, et al.
Publicado: (2016)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
por: Parini, Rossella, et al.
Publicado: (2020)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology
por: Navarro-Romero, Alba, et al.
Publicado: (2022)

Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program
por: Pintos-Morell, Guillem, et al.
Publicado: (2018)

Experimental and Numerical Characterization of a Hybrid Fabry-Pérot Cavity for Temperature Sensing
por: Lopez-Aldaba, Aitor, et al.
Publicado: (2015)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Liquid level sensor based on dynamic Fabry–Perot interferometers in processed capillary fiber
por: Roldán-Varona, Pablo, et al.
Publicado: (2021)

Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders
por: Seras‐Franzoso, Joaquin, et al.
Publicado: (2021)

Sistema para el control de servicios médicos para una empresa de agroquímicos
por: Pintos Ibañez, Ariadna
Publicado: (1999)

Fabry Disease With Concomitant Lewy Body Disease
por: Del Tredici, Kelly, et al.
Publicado: (2020)

Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease
por: Carmona, Sergio, et al.
Publicado: (2017)

Attention Deficits and ADHD Symptoms in Adults with Fabry Disease—A Pilot Investigation
por: Ali, Nadia, et al.
Publicado: (2021)

Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience
por: Quijada-Fraile, Pilar, et al.
Publicado: (2021)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Multimodality Cardiac Imaging in Cardiomyopathies: From Diagnosis to Prognosis
por: Casas, Guillem, et al.
Publicado: (2022)

Unilateral mydriasis secondary to ipratropium bromide in a critically ill patient
por: Santana-Cabrera, Luciano, et al.
Publicado: (2012)

El etiquetado de pacientes en atención primaria. El caso de la cronicidad
por: Riera Armengol, Laia
Publicado: (2017)

¿Una atención domiciliaria sin longitudinalidad?
por: Riera Armengol, Laia
Publicado: (2023)

Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
por: Stamerra, Cosimo A., et al.
Publicado: (2021)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Autonomous Car Parking System through a Cooperative Vehicular Positioning Network
por: Correa, Alejandro, et al.
Publicado: (2017)

Palabra y obra : escritos reunidos /
por: Fernández del Amo, José Luis
Publicado: (1995)

The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway
por: Del Pinto, Rita, et al.
Publicado: (2020)

Una visión sobre el ejercicio físico en mujeres menopáusicas prescrito de forma precoz y a distancia desde la Atención Primaria
por: Morell Esteve, Ariadna
Publicado: (2022)

Newborn screening for Fabry disease in the north-west of Spain
por: Colon, Cristobal, et al.
Publicado: (2017)

The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease
por: Furlano, Mónica, et al.
Publicado: (2022)

La violación a la garantía de audiencia en la imposición de sanciones a los especialistas de concursos mercantiles /
por: Pintos del Valle, Héctor
Publicado: (2014)

Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy
por: Ruiz de Garibay, Aritz Pérez, et al.
Publicado: (2012)

Fabry-Perot interferometers
por: Mora-Hernandez, G
Publicado: (1988)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
por: Rodríguez-Castejón, Julen, et al.
Publicado: (2022)

Cerebral hemodynamics and endothelial function in patients with Fabry disease
por: Segura, Tomás, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_keb0ii9pi5nlhggakbikp1f9s0